StageZero Life Science: Early Disease Detection

April 16, 2021

Detection of multiple disease states through whole blood

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia.

StageZero specializes in PCR testing for the early identification of cancer through blood. Further, the company is uniquely positioned to provide both COVID PCR testing (swab) and blood test analysis (Antibody testing).

Their full-service, telehealth platform includes access to physicians and phlebotomists. They can also prescribe and draw samples for individuals and groups. As they provide COVID-19 tests during this Pandemic, they also continue making progress with their mission to eradicate late-stage cancers through early detection.

StageZero's next generation test is Aristotle®, a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

"You've got to start fighting disease early and intervening early because that's where you change the actual course of the disease," says Chairman and CEO, James Howard-Tripp.

For more information on StageZero Life Sciences, Ltd. (TSX: SZLS) please click on the request investor info button.

You might also like

Brompton Funds: Global Healthcare Income & Growth ETF

Global Healthcare Management is active management and distributions program. It will gain knowledge of the established and emerging concept.

CEO Clips - Unicycive Therapeutics: Innovation to Improve Quality of Life For Patients Suffering from Kidney Diseases

Developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.

Content Broadcast on: BNN Bloomberg, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!